D. G. Maloney, Mechanism of action of rituximab, Anticancer Drugs, 2001.

I. Semac, C. Palomba, K. Kulangara, N. Klages, G. Van-echten-deckert et al.,

, Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells, Cancer Res, vol.63, issue.2, pp.534-574, 2003.

B. Bonavida, Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, vol.26, pp.3629-3665, 2007.

O. Manches, G. Lui, L. Chaperot, R. Gressin, J. Molens et al., In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas, Blood, vol.101, issue.3, pp.949-54, 2003.

S. H. Lim, S. A. Beers, R. R. French, P. Johnson, M. J. Glennie et al., Anti-CD20 monoclonal antibodies: historical and future perspectives, Haematologica, vol.95, issue.1, pp.135-178, 2010.

C. C. Mok, Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther, vol.8, pp.87-100, 2013.

A. G. Kattah, F. C. Fervenza, and D. Roccatello, Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases, Autoimmun Rev, vol.12, issue.8, pp.854-863, 2013.

R. B. Jones, C. Tervaert, J. W. Hauser, T. Luqmani, R. Morgan et al.,

, Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis, N Engl J Med, vol.363, issue.3, pp.211-231, 2010.

L. Guillevin, C. Pagnoux, A. Karras, C. Khouatra, O. Aumaître et al.,

, Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis, N Engl J Med, vol.371, pp.1771-80, 2014.

G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli et al., Rituximab for idiopathic membranous nephropathy, Lancet Lond Engl, vol.360, issue.9337, pp.923-927, 2002.

F. C. Fervenza, F. G. Cosio, S. B. Erickson, U. Specks, A. M. Herzenberg et al., Rituximab treatment of idiopathic membranous nephropathy, Kidney Int, 2008.

F. C. Fervenza, R. S. Abraham, S. B. Erickson, M. V. Irazabal, A. Eirin et al., Rituximab therapy in idiopathic membranous nephropathy: a 2-year study, Clin J Am Soc Nephrol CJASN, vol.5, issue.12, pp.2188-98, 2010.

L. H. Beck, F. C. Fervenza, D. M. Beck, R. Bonegio, F. A. Malik et al.,

, Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy, J Am Soc Nephrol JASN, vol.22, issue.8, pp.1543-50, 2011.

K. Dahan, H. Debiec, E. Plaisier, M. Cachanado, A. Rousseau et al.,

, Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up, J Am Soc Nephrol JASN, vol.28, issue.1, pp.348-58, 2017.

G. J. Pons-estel, R. Serrano, M. A. Plasín, G. Espinosa, and R. Cervera, Epidemiology and management of refractory lupus nephritis, Autoimmun Rev, vol.10, issue.11, pp.655-63, 2011.

D. Vita, S. Quartuccio, L. Isola, M. Mazzaro, C. Scaini et al., A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis, Arthritis Rheum, vol.64, issue.3, pp.843-53, 2012.

A. Gulati, A. Sinha, S. C. Jordan, P. Hari, A. K. Dinda et al., Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome: Multicentric Report, Clin J Am Soc Nephrol, vol.5, issue.12, pp.2207-2219, 2010.

G. Fernandez-fresnedo, A. Segarra, E. Gonzalez, S. Alexandru, R. Delgado et al., Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy, J Am Soc Nephrol JASN, vol.4, issue.8, pp.2729-2766, 2009.

V. Singh, D. Gupta, and A. Almasan, Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response, J Cancer Sci Ther, vol.7, issue.11, 2015.

T. Robak and E. Robak, New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies, BioDrugs Clin Immunother Biopharm Gene Ther, vol.25, issue.1, pp.13-25, 2011.

F. Baert, M. Noman, S. Vermeire, G. Van-assche, D. Haens et al., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, vol.348, issue.7, pp.601-609, 2003.

E. Schmidt, K. Hennig, C. Mengede, D. Zillikens, and A. Kromminga, Immunogenicity of rituximab in patients with severe pemphigus, Clin Immunol Orlando Fla, vol.132, issue.3, pp.334-375, 2009.

K. Smith, R. B. Jones, S. M. Burns, and D. Jayne, Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment, Arthritis Rheum, vol.54, issue.9, pp.2970-82, 2006.

D. Albert, J. Dunham, S. Khan, J. Stansberry, S. Kolasinski et al., Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus, Ann Rheum Dis, vol.67, issue.12, pp.1724-1755, 2008.

P. M. Ridker, J. Tardif, P. Amarenco, W. Duggan, R. J. Glynn et al., Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab, N Engl J Med, vol.376, issue.16, pp.1517-1543, 2017.

J. Golay, G. Semenzato, A. Rambaldi, R. Foà, G. Gaidano et al., Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs, vol.5, pp.826-863, 2013.

R. Jacobs, T. Langer-jacobus, M. Duong, K. Stahl, H. Haller et al.,

, Detection and quantification of rituximab in the human urine, J Immunol Methods, 2017.

C. E. Counsilman, C. M. Jol-van-der-zijde, J. Stevens, K. Cransberg, R. Bredius et al., Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome, Pediatr Nephrol, vol.30, issue.8, pp.1367-70, 2015.

K. Stahl, M. Duong, A. Schwarz, A. D. Wagner, H. Haller et al., Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome, Case Rep Nephrol, p.1372859, 2017.

J. Boye, T. Elter, and A. Engert, An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab, Ann Oncol Off J Eur Soc Med Oncol, vol.14, issue.4, pp.520-555, 2003.

R. M. Thurlings, O. Teng, K. Vos, D. M. Gerlag, L. Aarden et al., Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis, Ann Rheum Dis, vol.69, issue.2, pp.409-421, 2010.

G. Cartron, R. U. Trappe, P. Solal-céligny, and M. Hallek, Interindividual variability of response to rituximab: from biological origins to individualized therapies, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, issue.1, pp.19-30, 2011.

E. M. Vital, A. C. Rawstron, S. Dass, K. Henshaw, J. Madden et al., Reduceddose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion, Arthritis Rheum, vol.63, issue.3, pp.603-611, 2011.

E. M. Vital, S. Dass, M. H. Buch, K. Henshaw, C. T. Pease et al., B cell biomarkers of rituximab responses in systemic lupus erythematosus: B Cell Biomarkers in Rituximab Therapy for SLE, Arthritis Rheum, vol.63, issue.10, pp.3038-3085, 2011.

V. Strand, A. Balsa, J. Al-saleh, L. Barile-fabris, T. Horiuchi et al., Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review, BioDrugs Clin Immunother Biopharm Gene Ther, 2017.

S. Garcês, J. Demengeot, and E. Benito-garcia, The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a metaanalysis, Ann Rheum Dis, vol.72, issue.12, pp.1947-55, 2013.

G. J. Wolbink, M. Vis, W. Lems, A. E. Voskuyl, E. De-groot et al., Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum, vol.54, issue.3, pp.711-716, 2006.

G. M. Bartelds, C. A. Wijbrandts, M. T. Nurmohamed, S. Stapel, W. F. Lems et al., Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis, vol.66, issue.7, pp.921-927, 2007.

G. M. Bartelds, C. A. Wijbrandts, M. T. Nurmohamed, S. Stapel, W. F. Lems et al.,

, Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study, Ann Rheum Dis, vol.69, issue.5, pp.817-838, 2010.

B. Haraoui, J. Pelletier, and J. Martel-pelletier, Immunogenicity of biologic agents: a new concern for the practicing rheumatologist?, Curr Rheumatol Rep, vol.9, issue.4, pp.265-272, 2007.

N. Dunn, A. Juto, M. Ryner, A. Manouchehrinia, L. Piccoli et al., Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler Houndmills Basingstoke Engl, 2017.

K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. C. Kapetanovic et al., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab, Arthritis Rheum, vol.54, issue.12, pp.3782-3791, 2006.

J. Carrascosa, M. Van-doorn, M. Lahfa, F. O. Nestle, D. Jullien et al., Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies, J Eur Acad Dermatol Venereol JEADV, vol.28, issue.11, pp.1424-1454, 2014.

G. J. Wolbink and L. A. Aarden, Dijkmans B a. C. Dealing with immunogenicity of biologicals: assessment and clinical relevance, Curr Opin Rheumatol, vol.21, issue.3, pp.211-216, 2009.

M. Krishna and S. G. Nadler, Immunogenicity to Biotherapeutics -The Role of Anti-drug Immune Complexes. Front Immunol, vol.7, 2016.

M. Colucci, R. Carsetti, S. Cascioli, F. Casiraghi, A. Perna et al., Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome, J Am Soc Nephrol JASN, vol.27, issue.6, pp.1811-1833, 2016.

A. Parenky, H. Myler, L. Amaravadi, K. Bechtold-peters, A. Rosenberg et al., Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial, J Am Acad Dermatol, vol.16, issue.3, pp.534-576, 2004.

A. Menter, S. R. Feldman, G. D. Weinstein, K. Papp, R. Evans et al., A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis, J Am Acad Dermatol, vol.56, issue.1, pp.31-32, 2007.

S. Goto, H. Goto, R. Tanoshima, H. Kato, H. Takahashi et al., Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura, Int J Hematol, vol.89, issue.3, pp.305-314, 2009.

D. Jullien, J. C. Prinz, and F. O. Nestle, Immunogenicity of biotherapy used in psoriasis: the science behind the scenes, J Invest Dermatol, vol.135, issue.1, pp.31-39, 2015.

F. B. Vincent, E. F. Morand, K. Murphy, F. Mackay, X. Mariette et al., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis, vol.72, issue.2, pp.165-78, 2013.

K. Bendtzen, Anti-TNF-? biotherapies: perspectives for evidence-based personalized medicine, Immunotherapy, vol.4, issue.11, pp.1167-79, 2012.

S. Garcês, M. Antunes, E. Benito-garcia, J. C. Da-silva, L. Aarden et al., A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies, Ann Rheum Dis, vol.73, issue.6, pp.1138-1181, 2014.